Comparing the current results to its competitors, Bioaffinity Technologies Inc reported Revenue increase in the 2 quarter 2026 by 18.99 % year on year. The sales growth was above Bioaffinity Technologies Inc 's competitors' average revenue growth of 15.29 %, achieved in the same quarter.
Bioaffinity Technologies Inc 's Comment on Competition and Industry Peers
CyPath® Lung is a noninvasive lung cancer test designed for adults at high risk of lung cancer, particularly those with small or indeterminate pulmonary nodules detected by low dose computed tomography (LDCT). The test utilizes sputum analysis through flow cytometry, distinguishing it from molecular tests used by competitors. CyPath® Lung has demonstrated high published performance metrics, although it has not been directly compared to competing tests. It is compared to LungLB, a test marketed by LungLife AI in the United States, which has lower sensitivity and specificity and was evaluated in a population with a higher disease prevalence than CyPath® Lung's target group. The company holds a patent portfolio comprising 19 issued U.S. and international patents related to its technology and diagnostic applications.
Overall company sales advanced by 18.99 % Bioaffinity Technologies Inc outperformed its competitors in this segment and improved market share, to approx. 0.05 %. << More on BIAF Market Share.
*Market share is calculated based on total revenue.
Publicly Traded Peers of Bioaffinity Technologies Inc
Caredx Inc Share Performance
+13.55%
30 Days
Caredx Inc
Profile
Caredx Inc is a precision medicine company with a business model focused on transplant diagnostics. They develop and commercialize non-invasive tests to identify and monitor organ transplant rejection. By offering innovative solutions and services in the transplant field, Caredx Inc aims to improve outcomes for patients and provide healthcare professionals with valuable information to guide treatment decisions.
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Fortrea Holdings Inc is a company that operates through its subsidiaries in the business of software and technology services, providing innovative solutions and products to its clients. Its business model focuses on developing and delivering custom software applications, digital platforms, and consulting services to cater to the specific needs of various industries.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Sources:
Bioaffinity Technologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bioaffinity Technologies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
